Grifols, S.A. (GRFS) vs MIRA Pharmaceuticals, Inc. (MIRA)
Grifols, S.A. and MIRA Pharmaceuticals, Inc. are both Drug Manufacturers General companies. Grifols, S.A. is the larger, with a market value of $1.9B against $35.3M — 52.7× the size. MIRA Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Grifols, S.A. trades at 8.1×. Grifols, S.A. has the higher net margin (5.54% vs 0.00%) and the higher return on invested capital (0.00% vs −12,016.1%). Across the 13 metrics below, Grifols, S.A. leads on 10 and MIRA Pharmaceuticals, Inc. on 3.
Valuation
Profitability
| Metric | GRFS | MIRA | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 37.45% | — | 72.77% |
| Operating margin | 16.43% | 0.00% | 18.90% |
| Net margin | 5.54% | 0.00% | 8.27% |
| Free cash flow margin | 0.00% | 0.00% | 17.25% |
| Return on equity | 0.00% | (710.85%) | 6.97% |
| Return on assets | 0.00% | (684.27%) | 2.76% |
| Return on invested capital | 0.00% | (12,016.10%) | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack